Carolina Capital Consulting Will Join Focus Partner Firm Buckingham Strategic Wealth, Establishing Buckingham s Presence in North Carolina theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
Share:
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) Agile Therapeutics, Inc. (NASDAQ:AGRX), a women s healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla
® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI 25 kg/m
2 and women with BMI 25-30 kg/m
2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30 – May 2.
Twirla was approved based on the Phase 3 SECURE Trial, a United States, multicenter, single-arm, open-label, 13-cycle trial that evaluated the efficacy, safety and tolerability of Twirla in 2,032 healthy women. Twirla is a combination of levonorgestrel and ethinyl estradiol indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.
EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse
PolyPeptide Group legt IPO-Angebotspreis bei CHF 64.00 pro Aktie fest und beginnt Handel an der Schweizer Börse
29.04.2021 / 07:00
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
FOR RELEASE IN SWITZERLAND - THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS CONTAINED HEREIN.
EQS-News: PolyPeptide Group legt IPO-Angebotspreis bei CHF 64 00 pro Aktie fest und beginnt Handel an der Schweizer Börse boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.